Altnvest
LibraryNexPoint Life Sciences III DST
Back to Offering

Use of Proceeds

Processed

NexPoint Life Sciences III DST

Proceeds from $30,661,253 in equity and $31,300,000 in debt are applied to purchase price and $2,866,827 in upfront fees and offering costs.

Total Fees & Expenses

$2,866,827

% of equity

9.35%

% of offering

4.63%

Where the offering proceeds go

Acquisition Cost$59.09M95.4%
Offering Expenses$2.87M4.6%

Total fees & expenses

$2.87M

4.63% of offering

Offering expenses

$2.87M

4.63% of offering

Reserves held

— of offering

Cost of Acquisition

ItemAmount% Equity% Offering
Title & Recording Costs$12,4200.04%0.02%
Finance Expenses$187,3110.61%0.30%
Total Acquisition Cost$59,094,426192.73%95.37%
Total Acq. Cost (Reserves)$59,094,426192.73%95.37%

Offering Expenses

ItemAmount% Equity% Offering
Dealer Fee$843,1842.75%1.36%
BD Due Diligence Allowance$413,9271.35%0.67%
BD Marketing Allowance$413,9271.35%0.67%
O&O Expenses$183,9680.60%0.30%
Total Offering Expenses$2,866,8279.35%4.63%
Total Fees / Expenses$2,866,8279.35%4.63%
Total Upfront Fees (Reserves)$2,866,8279.35%4.63%

Strengths

  • Proceeds fully capitalize acquisition and transaction expenses.
  • Financing expenses isolated at $187,311.

Concerns

  • Upfront fee load represents 9.35% of acquisition cost.
  • Total fees and expenses consume $2,866,827.